'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
'藥品兄弟'馬丁·香克利告訴投資者要開空SAVA，股票在第三階段更新後下跌超過80%。
Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.
cassava sciences（納斯達克:SAVA）股票週一下跌，該公司分享了針對阿爾茨海默病治療的第三階段試驗的最新消息，這一消息受到市場廣泛關注。
Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock's crash Sunday night.
馬丁·舒克雷利，藥品行業內的知名人物，預測了該股票在週日夜間的崩盤。
What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, sending shares significantly lower to start the trading week.
發生了什麼：cassava sciences報告指出，其關於Simufilam的ReThink-ALZ研究的第三階段初步結果未能達到主要終點，使得股票在交易周初大幅下跌。
The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety...
該公司表示，計劃在即將舉行的會議上展示...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間